- 询价
- Miltenyi Biotec
- 德国
- 130-120-356
- 2025年12月09日
- Flow cytometry, Mass cytometry
- human cell line
- human
企业认证
相关产品推荐更多 >
CD24 Antibody, anti-human, Biotin, REAfinity™, 30 tests in 60 µL
询价CD353 (SLAMF8) Antibody, anti-human, Biotin, REAfinity™, 30 tests in 300 µL
询价
TCR Vβ11 Antibody, anti-mouse, Biotin, REAfinity™, 9 µg in 300 µL
询价CD21 Antibody, anti-human, PE, REAfinity™, 30 tests in 60 µL
询价FOLR1 Antibody, anti-human, Vio® Bright V423, REAfinity™, 30 tests in 60 µL
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
CD336 (NKp44)
- 亚型：
recombinant human IgG1
- 形态：
Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide.
- 保存条件：
避光，4-8℃
- 克隆性：
REA1163
- 标记物：
PE
- 适应物种：
human
- 保质期：
24个月
- 供应商：
Miltenyi Biotec
- 宿主：
human cell line
- 应用范围：
Flow cytometry, Mass cytometry
- 浓度：
1:50
- 抗体英文名：
CD336 (NKp44) Antibody, anti-human, REAfinity™
- 抗体名：
CD336 (NKp44) Antibody, anti-human, REAfinity™
- 规格：
100 tests in 200 µL
Identification and enumeration of CD336 (NKp44)+ cells by flow cytometryClone REA1163 recognizes the human CD336 antigen, also known as NKp44. CD336 is a member of the natural cytotoxicity receptor (NCR) family which trigger cytotoxicity in natural killer (NK) cells. CD336 is directly involved in target cell recognition and lysis and is only expressed by activated NK cells, e.g., NK cells cultured in the presence of interleukin 2 (IL-2). Freshly isolated, resting NK cells do not express CD336. | Additional information: Clone REA1163 displays negligible binding to Fc receptors.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
Vitale, M. et al. (1998) NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J. Exp. Med. 187: 2065–2072. | Sivori, S. et al. (2000) 2B4 functions as a co-receptor in human NK cell activation. Eur. J. Immunol. 30: 787–793. | Moretta, A. et al. (2001) Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19: 197–223. | Chaput, N. et al. (2013) Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR+ NK cell levels correlate with disease outcome. Oncoimmunology 2 (2): e23080.
技术资料暂无技术资料 索取技术资料
文献支持
CD336 (NKp44) Antibody, anti-human, PE, REAfinity™, 100 tests in 200 µL
询价
